The FDA's critique of the anturane reinfarction trial

N Engl J Med. 1980 Dec 18;303(25):1488-92. doi: 10.1056/NEJM198012183032534.
No abstract available

MeSH terms

  • Clinical Trials as Topic / methods*
  • Death, Sudden* / etiology
  • Double-Blind Method
  • Humans
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Placebos
  • Random Allocation
  • Research Design
  • Sulfinpyrazone / therapeutic use*
  • United States
  • United States Food and Drug Administration*

Substances

  • Placebos
  • Sulfinpyrazone